Glucagon like peptide 1 receptor agonists : a therapy for diabetes management
ABSTRACT: Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in gly cated hemoglobin A. Methods: A bibliographic search was made on Medline®...
- Autores:
-
Rojas Henao, Natalia Andrea
Granados Vega, Elkyn Johan
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2018
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/23997
- Acceso en línea:
- http://hdl.handle.net/10495/23997
- Palabra clave:
- Diabetes Mellitus Tipo 2
Diabetes Mellitus, Type 2
Hipoglucemia
Hypoglycemia
Péptido 1 Similar al Glucagón
Glucagon-Like Peptide 1
Hemoglobina A
Hemoglobin A
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| Summary: | ABSTRACT: Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in gly cated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with gly cemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic con trol, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety |
|---|